Location of Repository

Immunosuppressive drug interactions and resistance in mononuclear cells from renal transplant patients

By Michael Paul Delaney


Existing anti-rejection drug regimes are inadequate since patients receive drugs despite\ud serious side effects and poor response. New drugs are being developed\ud which ultimately may allow for prescribing of rational, patient-specific\ud immunosuppressive drug protocols. During this thesis the investigation of\ud lymphocyte responses from renal transplant recipients to the immunosuppressant\ud drugs Cyclosporin A (Cy A), FK506 and SDZ RAD were explored to understand\ud the variation in sensitivity of lymphocytes to Cy A and FK506, the development of\ud drug resistance, including resistance mechanisms, and the interactions between\ud FK506 and SDZ RAD.\ud Cy A and FK506 are substrates for P-glycoprotein (P-gp), the product of the\ud multidrug-resistance (MDR1) gene in man. A hypothesis established during this\ud thesis was that P-gp dependent mechanisms explain variations in lymphocyte\ud sensitivities to Cy A and FK50.\ud Lymphocytes from renal transplant recipients were assessed for their sensitivity to\ud Cy A and FK506 and subsequently for P-gp expression and functional activity by\ud flow cytometry. In further lymphocyte cultures the effect of the specific P-gp\ud inhibitor, PSC 833 on sensitivity was investigated. Finally, the effects of the\ud combination of FK506 and SDZ RAD in lymphocyte cultures were analysed.\ud Results demonstrate a wide range in lymphocyte sensitivity to both Cy A and\ud FK506, with the development of selective resistance to the drug used for\ud treatment. All patients demonstrated P-gp functional activity but P-gp expression\ud was not demonstrable. P-gp function did not account for the variation in\ud lymphocyte sensitivity. There was no evidence of antagonism of effect of SDZ\ud RAD in combination with FK506.\ud In conclusion, these results suggest that non-P-gp mechanisms account for\ud variations in lymphocyte sensitivity to Cy A and FK506. Combination therapy\ud with SDZ RAD and FK506 is unlikely to be antagonistic in future treatment\ud protocols

Topics: RM
OAI identifier: oai:wrap.warwick.ac.uk:3703

Suggested articles



  1. (1995). 3'-keto-Bmtl ]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
  2. (1984). A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses. doi
  3. (1997). A Comparison of tacrolimus (FK506) and cyclosporin for immunosuppression after cadaveric renal transplantation. For The FK506 Kidney Transplant Study Group. doi
  4. (1989). A cytosolic binding protein for the immunosuppressant FK506 has pcptidyl. prolyl isomerase activity but is distinct from cyclophilin. doi
  5. (1996). A History of Transplantation Immunology (First Edition):
  6. (1973). A human cell line from a pleural effusion derived from a breast carcinoma.
  7. (1994). A mammalian protein targeted by Gl-arresting rapamycin-receptor complex. doi
  8. (1999). A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. doi
  9. (1995). A prospective randomised trial of FK506"based immunosuppression after renal transplantation. doi
  10. (1989). A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. doi
  11. (2000). Absorption Profiling- A novel method for monitoring Neoral in kidney transplantation that reduces rejection and nephrotoxicity. doi
  12. (1994). Acute rejection episodes--best predictor of long-term primary cadaveric renal transplant survival.
  13. (1988). Adverse influence of recipient lymphoid resistance to in vitro immunosuppression on the outcome of kidney transplants. doi
  14. (1996). An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. doi
  15. (1995). An analysis of predictors of long-term cadaveric renal allograft survival. Clinical Transplants pp 282-288. Edited by
  16. (1998). An endothelin-transforming growth factor beta pathway in the nephrotoxicity of immunosuppressive drugs. doi
  17. (1992). An Illustrated History of Organ Transplantation.
  18. (1992). Analyses of the UNOS Scientific Renal Transplant Registry at three years--early events affecting transplant success. doi
  19. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. doi
  20. (1998). Cell adhesion molecules in clinical renal transplantation. doi
  21. (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. doi
  22. (1989). Cellular requirements for renal allograft rejection in the athymic nude rat. doi
  23. (1995). Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Therapeutic Drug Monitoring doi
  24. (1991). Chemistry and biology of the immunophilins and their immunosuppressive ligands. doi
  25. (1999). Chronic rejection in kidney transplants. An in-depth review. doi
  26. (1987). Clarification of the chromosomal assignment of the human P-glycoprotein/mdrl gene: possible coincidence with the cystic fibrosis and c-met oncogene. doi
  27. (1994). Clinical Significance of in vitro donor specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR. doi
  28. (1992). Cloning of the gamma chain of the human IL-2 receptor. doi
  29. (1997). Comparative effect of verapamil, cyclosporin A and SDZ PSC 833 on rhodamine 123 transport and cell cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotein. Anticancer Drugs 8,869-875. doi
  30. (1991). Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogeninduced cytokine production and lymphoproliferation.
  31. (1995). Comparative Study of Multidrug Resistance Evaluated by Means of the Quantitative Immunohistoehemical Detection of P-Glycoprotein and the Functional Release of Rhodamine 123. doi
  32. (1993). Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. doi
  33. (2000). Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. doi
  34. (1989). Contingent genetic regulatory events in T lymphocyte activation. doi
  35. (1999). Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice.
  36. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. doi
  37. (1989). Cyclophilin and peptidyl-prolyl cis-trans isomerase arc probably identical proteins. doi
  38. (1984). Cyclophilin: a specific cytosolic binding protein for cyclosporin A. doi
  39. (1998). Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein. doi
  40. (1978). Cyclosporin A in patients receiving renal allografts from cadaver donors. doi
  41. (1979). Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. doi
  42. (1996). Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.
  43. (1996). Cyclosporin nephrotoxicity in heart and lung transplant patients. doi
  44. (1988). Cyclosporine metabolism in human liver: identification of a cytochrome P-450111 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics doi
  45. (1994). Cyclosporine-A, FK506, and rapamycin - binding to immunophilins and biological action. doi
  46. (1984). Cyclosporine: five years' experience in cadaveric renal transplantation. The New England doi
  47. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metabolism and Disposition
  48. (1994). Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. doi
  49. (1992). Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. doi
  50. (1991). Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. doi
  51. (1998). Differential activity of P-glycoprotein in normal blood lymphocyte subsets. doi
  52. (1994). Differential expression of cyclophilin isoforms during keratinocyte differentiation.
  53. (2001). Differential Influence Of Neoral Versus Sandimmune On Everolimus Pharmacokinetics: A Clinically Relevant Drug Interaction. doi
  54. (1987). Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. doi
  55. (1990). Distinct mechanisms of suppression of murinc T cell activation by the related macrolides FK-506 and rapamycin.
  56. (1995). Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. doi
  57. (1996). Effect of Gly to Val substitution in human P-glycoprotein on the reversal activity of PSC 833.
  58. (1983). Effects of cyclosporin A on the metabolism of unstimulated and mitogen-activated lymphocytes.
  59. (1995). Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. doi
  60. (2000). Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. doi
  61. (1990). Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. doi
  62. (1991). Expression and Activity of PGlycoprotein, a Multidrug Efflux Pump, in Human Hematopoietic Stem Cells. doi
  63. (1992). Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.
  64. (1987). Expression of a full cDNA for the human 'MDRI' gene confers resistance to colchicine, doxorubicin, and vinblastine. doi
  65. (1989). Expression of a Multidrug Resistance Gene in Human Cancers. doi
  66. (1992). Expression of Pglycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.
  67. (1996). Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells. doi
  68. (1995). Expression pattern of MRP in human tissues and adult solid tumour cell lines. doi
  69. (1994). Factors influencing outcome in cadaveric renal transplantation. doi
  70. (1991). Firstpass metabolism of cyclosporin by the gut. doi
  71. (1994). FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. doi
  72. (1995). FK506 versus cyclosporin in the prevention of renal allograft rejection- European pilot study: six-week results. doi
  73. (1997). Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. doi
  74. (1995). Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytomctry. doi
  75. (1989). Functional domain structure of calcineurin A: mapping by limited proteolysis. doi
  76. (2000). Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. doi
  77. (1986). Functional role for the 170-to180- KD glycoprotein specific to drug resistant tumour cells as revealed by monoclonal antibodies. doi
  78. (2000). Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clinical Pharmacology and Therapeutics doi
  79. (1999). Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT.
  80. (1993). Genistein modulates the decreased drug accumulation in non-P-glycoprotcin mediated multidrug resistant tumour cells. doi
  81. (2001). Geographical Variation In Skin Cancer Risk Post-Transplantation: A Matched Cohort Comparison Between England And Australia.
  82. (1998). Historical Overview. In doi
  83. (2001). HLA Matching For Kidney Transplantation Significantly Enhances Survival, Reduces Acute Rejection And Minimises Sensitisation.
  84. (1996). How best to use Tacrolimus (FK506) for treatment of Steroid- and OKT3-resistant rejection after renal transplantation. doi
  85. (1993). How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture.
  86. (1997). Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. doi
  87. (1993). Human P-glycoprotein transports Cyclosporin A and FK506. doi
  88. (1995). Identification of a graft versus host disease-associated human minor histocompatibility antigen. doi
  89. (1992). Identification of calcineurin as a key signaling enzyme in T-cell activation. doi
  90. (1989). Identification of members of the P-glycoprotein multigene family.
  91. (1992). Identification of rifampin-inducible P450111A4 (CYP3A4) in human small bowel enterocytes. doi
  92. (1999). Immunobiology of solid organ transplantation.
  93. (1994). Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumour cells by monoclonal antibodies.
  94. (1990). Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.
  95. (1994). Immunophilins in protein folding and immunosuppression. FASE3
  96. (1997). Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacy. Clinical Pharmacology and Therapeutics doi
  97. (1996). Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. doi
  98. (2000). Improved graft survival after renal transplantation in the United States, doi
  99. (1999). Indirect allorecognition is involved in both acute and chronic allograft rejection. Transplantation doi
  100. (1997). Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. doi
  101. (1993). Inhibition of PICA induced mononuclear proliferation by FK506 in combination with cyclosporinc, methylprednisolone, 6-mercaptopurine and mycophenolic acid. doi
  102. (1989). Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. doi
  103. (1995). Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation. doi
  104. (1989). Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's. doi
  105. (1995). Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. doi
  106. (1996). Intragraft TGF-beta I mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. doi
  107. (1996). Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes.
  108. (1995). Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. doi
  109. (1980). Localization of mitochondria in living cells with rhodamine 123. doi
  110. (1996). Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. doi
  111. (2001). Longitudinal assessment of everolimus in de novo renal transplant recipients over the first posttransplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clinical Pharmacology and Therapeutics doi
  112. (1984). Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. doi
  113. (1991). lymphocyte proliferation by rapamycin.
  114. (1995). MDR1 gene expression in lymphocytes of patients with renal transplants. doi
  115. (1990). Migration and maturation of Langerhans cells in skin transplants and explants.
  116. (1970). Mixed lymphocyte cultures produce effector cells: model in vitro for allograft rejection. doi
  117. Monoclonal antibodies against P-glcoprotein, an MDRI gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.
  118. (1994). Multicenter FKSO6 Liver Study Group.
  119. (1997). Multicenter randomised trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. A Report of The European Tacrolimus Multicenter Renal Study Group. doi
  120. (1987). Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. doi
  121. (1997). Multidrug Resistance Protein (MRP) Expression in Retinoblastoma Correlates with the Rare Failure of Chemotherapy despite Cyclosporine for Reversal of P-Glycoprotein.
  122. (1995). Multidrug Transporter P-Glycoprotein 170 as a Differentiation Antigen on Normal Human Lymphocytes and Thymocytes: Modulation with Differentiation Stage and During Aging. doi
  123. (1994). Multifactorial Analysis of Renal Transplants reporting to the United Network for Organ Sharing Registry: a 1994 update.
  124. (2001). National Transplant Database activity for 01/01/00-31/01/00.
  125. (1999). Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. doi
  126. (1999). Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. doi
  127. (1995). New flow cytometric method for detection of minimally expressed multidrug resistance Pglycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate. doi
  128. (1994). No effect of H-Y minor histocompatibility antigen in zcromismatched living-donor renal transplants. doi
  129. (1987). Novel immunosuppressive agent, FK506. In vitro effects on the cloned T Cell Activation.
  130. (1996). One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. doi
  131. (1997). Optimal immunocytochemical and flow cytometric detection of P"gp, MRP and LRP in childhood acute lymphoblastic leukemia. doi
  132. (2000). Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. doi
  133. (1992). Overexpression of a Transporter Gene in a Multidrug"Resistant Human Lung Cancer Cell Line. doi
  134. (1997). P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. doi
  135. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. doi
  136. (2000). P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
  137. (1994). Pglycoprotein expression and function in circulating blood cells from normal volunteers.
  138. (2000). Pharmacokinetic validation of Neoral absorption profiling. doi
  139. (2001). Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. doi
  140. Pharmacokinetics of FK 506 in transplant patients. Transplantation doi
  141. (1996). Phase I Study of Etoposide With SDZ PSC 833 as a Modulator of Multidrug Resistance in Patients With Cancer.
  142. (1985). Phytohemagglutinin binds to the 20-kDa molecule of the T3 complex. doi
  143. (1995). Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Therapeutic Drug Monitoring doi
  144. (1991). Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplantation doi
  145. (1995). Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. doi
  146. (1992). Protein folding in the cell. doi
  147. (1998). PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Review 17,163-168.
  148. (1996). Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. doi
  149. (1994). Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
  150. (1997). Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. doi
  151. (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORS. doi
  152. (1994). Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograf3 rejection. doi
  153. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. doi
  154. (1991). Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplantation
  155. (1992). Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases. doi
  156. (1996). Rapid shuttling of NF-AT in discrimination of Cat+signals and immunosuppression. doi
  157. (1986). Recipient lymphocyte sensitivity to methyl prednisolone affects cadaver kidney transplant survival. doi
  158. Registry 2000. UK Renal Registry, doi
  159. (1996). Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/ Dox cell line subclones. doi
  160. (1995). Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.
  161. (1996). Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. doi
  162. (1991). Resistance modification by PSC833, a novel non-immunosuppressive cyclosporin. doi
  163. (1991). Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. doi
  164. (1982). Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. doi
  165. (1974). Restriction of in vitro T cellmediated cytotoxicity in lymphocytic choriomeningitis within a syngencic or semiallogeneic system. doi
  166. (1999). Rethinking chronic allograll nephropathy: the concept of accelerated senescence.
  167. (1996). Rhodamine 123-efflux from hematopoietic subpopulations and leukacmic blast populations marked by PerCP-conjugated monoclonal antibodies. doi
  168. (1995). Risk of neoplasia in renal transplant patients. doi
  169. (1995). Role of glutathione in the export of compounds from cells by the mul tidrug-resi stanceassociated protein. doi
  170. (1997). Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology and Therapeutics doi
  171. (1997). SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. doi
  172. (1995). Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. doi
  173. (1999). Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. doi
  174. (2002). Strategies to improve long-term outcomes after renal transplantation. The New England doi
  175. (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. doi
  176. (1996). Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. doi
  177. (1997). Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. doi
  178. (1991). Survival trends in long-term first cadaver-donor kidney transplants. Clinical Transplants pp 225-235. Edited by
  179. (1990). T-lymphocyte-antigen interactions in transplant rejection. doi
  180. (1988). T4 cell activation by immobilized phytohemagglutinin: differential capacity to induce IL-2 responsiveness and IL-2 production.
  181. (1997). Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. doi
  182. (1997). Tacrolimus rescue therapy for renal allograft rejection-five year experience. doi
  183. (1997). Tacrolimusrapamycin combination therapy for experimental autoimmune uvcoretinitis.
  184. (1989). The Biochemistry of P-GlycoprotcinMediated Multidrug Resistance. doi
  185. (2001). The C3435T mutation in the human MDRI gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.
  186. (1997). The CD40 pathway in allograft rejection, acceptance, and tolerance. doi
  187. (1995). The drug resistance-related protein LRP is the human major vault protein. doi
  188. (1994). The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. doi
  189. (1982). The effect of serum, EGF, PGF2 alpha and insulin on S6 phosphorylation and the initiation of protein and DNA synthesis.
  190. (1994). The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. doi
  191. (1992). The immunosuppressive and toxic effects of FK-506 arc mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. doi
  192. (1990). The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.
  193. (1998). The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplantation doi
  194. (1990). The molecular basis of alloreactivity. Immunology Today 11,83.88. doi
  195. (1993). The nature of allorecognition. doi
  196. The RAPAMUNE Global Study Group_(2001). A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. doi
  197. (1988). The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. doi
  198. (1995). The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. doi
  199. (1999). The role of intestinal P-glycoprotcin in the interaction of digoxin and rifampicin. doi
  200. (1993). The role of the CD28 receptor during T cell responses to antigen. doi
  201. (1987). The T-cell antigen receptor regulates sustained increases in cytoplasmic free Ca2+ through extracellular Ca2+ influx and ongoing intracellular Ca2+ mobilization.
  202. (1999). The temporal profile of calcineurin inhibition by cyclosporine in vivo. doi
  203. (2000). Time dependency of factors affecting renal allograft survival.
  204. (1990). Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. doi
  205. (1988). Use of fluorescent dyes as molecular probes for the study of multidrug resistance. doi
  206. (1996). Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.